Immunotherapy of Cancer

1. Front Matter

   Pages i-xii

   PDF

2. Discovery of Target Molecules for Cancer Immunotherapy by Genetic and Bioinformatic Approaches

   • Özlem Türeci, Thorsten Klamp, Michael Koslowski, Sebastian Kreiter, Ugur Sahin

   Pages 1-19

3. Current Strategies for the Identification of Immunogenic Epitopes of Tumor Antigens

   • Ludmila Müller, Stephanie McArdle, Evelyna Derhovanessian, Thomas Flad, Ashley Knights, Robert Rees et al.

   Pages 21-44

4. Current and Future Role of Natural-Killer Cells in Cancer Immunotherapy

   • Lisa M. Harlan, Julie Y. Djeu

   Pages 45-58

5. The Role of Immune Monitoring in Evaluating Cancer Immunotherapy

   • Holden T. Maecker

   Pages 59-72

6. Statistical Analysis of Immune Response Assays in Cancer Immunotherapy Trials

   • Susan Groshen

   Pages 73-85

7. DNA Vaccines for Cancer Immunotherapy

   • Heesun Kwak, Howard L. Kaufman

   Pages 87-114

8. Dendritic Cells

   • Weiping Zou, Tyler J. Curiel

   Pages 115-126

9. Different Approaches to Dendritic Cell-Based Cancer Immunotherapy

   • Noweeda Mirza, Dmitry Gabrilovich

   Pages 127-138

10. Anti-Idiotype Antibody Vaccines for the Immunotherapy of Cancer

    • Malaya Bhattacharya-Chatterjee, Nitin Rohatgi, Sunil K. Chatterjee, Asim Saha, Rakesh Shukla, Kenneth A. Foon

    Pages 139-149

11. Autologous Tumor-Derived Heat Shock Protein Vaccine as a New Paradigm for Individualized Cancer Therapeutics

    • Jie Dai, Zihai Li

    Pages 151-166

12. Tumor-Reactive T-Cells for Adoptive Immunotherapy

    • Helga Bernhard, Julia Neudorfer, Kerstin Gebhard, Heinke Conrad, Dirk H. Busch, Christian Peschel

    Pages 167-179

13. T-Cell Adoptive Immunotherapy of Cancer

    • Peter A. Cohen, Mohamed Awad, Suyu Shu

    Pages 181-212

14. Retroviral-Mediated Gene Transfer for Engineering Tumor-Reactive T-Cells

    • Jeffrey J. Roszkowski, Michael I. Nishimura

    Pages 213-233

15. Harnessing the Potential of Graft-vs-Tumor

    • Nancy M. Hardy, Michael R. Bishop

    Pages 235-261

16. Tumor-Induced Immune Suppression and Immune Escape

    • Michael Campoli, Soldano Ferrone

    Pages 263-284

17. The Tumor Microenvironment

    • George Coukos, Jose-Ramon Conejo-Garcia

    Pages 285-301

18. Manipulation of Lymphocyte Homeostasis for Enhancing Antitumor Immunity

    • Eduardo Davila, Esteban Celis

    Pages 303-316

19. Fast-Lane Evolution in the Tumor Microenvironment

    • Gabriella Marincola, Francesco M. Marincola

    Pages 317-329

20. Manipulating Immunological Checkpoints to Maximize Antitumor Immunity

    • Leisha A. Emens, R. Todd Reilly, Elizabeth M. Jaffee

    Pages 331-353

Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully examined.

• Antigen
• T cell
• cell
• cell therapy
• clinical trial
• cytokine
• cytokines
• imaging
• imaging techniques
• immunotherapy
• innate immunity
• interferon
• lymphoma
• tumor
• vaccine

From the reviews:

"Immunotherapy of Cancer provides in 28 chapters a comprehensive overview of experimental and clinical achievements in tumor immunology. Each chapter is designed to give the reader the scientific basis behind the discussed therapy and outline basic theory, as well as practical treatment applications. … The book belongs to the successful series of publications Cancer Drug Discovery and Development from Humana Press. It will be of interest to clinicians and to laboratory cancer researchers … ." (Cestmir Altaner, Neoplasma, Vol. 54 (2), March, 2007)

• University of Washington School of Medicine, Seattle

  Mary L. Disis

Policies and ethics